Bionyra Pharma emerged from stealth after raising $165 million in an oversubscribed Series A to develop next-generation biologics for severe inflammatory and immune-driven diseases. The new clinical-stage company was co-founded by Frédéric Marrache, MD, PhD, with investment led by Jeito Capital and Sofinnova Partners. Backers also include Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures. The board additions include senior partners from Jeito, Sofinnova, Arkin Bio, and Sanofi Ventures, reflecting a strategy anchored in immunology and target/pathway selection. For the sector, the launch highlights continued appetite for differentiated biologic platforms in inflammatory indications, even as diligence intensifies around translational packages and competitive differentiation.